(Q36830130)

16 August 2017

1 reference

title

Etanercept: a review of its use in the management of rheumatoid arthritis (English)

1 reference

16 August 2017

1 reference

3

Lesley J Scott

1 reference

Katherine A Lyseng-Williamson

16 August 2017

series ordinal

2

object named as

Katherine A Lyseng-Williamson

1 reference

16 August 2017

1

Sohita Dhillon

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

67

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

1211-1241

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767080-00011

16 August 2017

exact match

0 references

cites work

The pharmacokinetics of etanercept in patients with heart failure

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767080-00011

Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies

21 January 2018

1 reference

12 December 2020

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

1 reference

12 December 2020

Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis

1 reference

12 December 2020

The influence of a polymorphism at position -857 of the tumour necrosis factor gene on clinical response to etanercept therapy in rheumatoid arthritis

1 reference

12 December 2020

Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors.

1 reference

12 December 2020

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

1 reference

12 December 2020

1 reference

12 December 2020

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

12 December 2020

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

12 December 2020

The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis

1 reference

12 December 2020

Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study

1 reference

12 December 2020

Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis

1 reference

12 December 2020

New therapies for rheumatoid arthritis

1 reference

12 December 2020

Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability

1 reference

12 December 2020

Musculoskeletal manifestations and autoimmune diseases related to new biologic agents

1 reference

12 December 2020

Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis

1 reference

12 December 2020

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

12 December 2020

Association between etanercept use and employment outcomes among patients with rheumatoid arthritis

1 reference

12 December 2020

The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept

1 reference

12 December 2020

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

12 December 2020

The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications

1 reference

12 December 2020

Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis

1 reference

12 December 2020

Nerve growth factor and brain-derived neurotrophic factor levels in patients with rheumatoid arthritis treated with TNF-alpha blockers.

1 reference

12 December 2020

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

1 reference

12 December 2020

Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience

1 reference

12 December 2020

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report

1 reference

12 December 2020

Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)

1 reference

12 December 2020

A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis

1 reference

12 December 2020

Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.

1 reference

12 December 2020

Considerations with the use of biological therapy in the treatment of rheumatoid arthritis

1 reference

12 December 2020

Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.

1 reference

12 December 2020

British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years).

1 reference

12 December 2020

Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

1 reference

12 December 2020

Immune function in patients with rheumatoid arthritis treated with etanercept

1 reference

12 December 2020

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register

1 reference

12 December 2020

Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.

1 reference

12 December 2020

Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis

1 reference

12 December 2020

Does route of administration affect the outcome of TNF antagonist therapy?

1 reference

12 December 2020

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

1 reference

12 December 2020

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry

1 reference

12 December 2020

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

1 reference

12 December 2020

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis

1 reference

12 December 2020

Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations

1 reference

12 December 2020

Safety of tumour necrosis factor-alpha antagonists

1 reference

12 December 2020

Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials

1 reference

12 December 2020

Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study

1 reference

12 December 2020

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial

1 reference

12 December 2020

The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis

1 reference

12 December 2020

Absence of a pharmacokinetic interaction between etanercept and warfarin

1 reference

12 December 2020

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison

1 reference

12 December 2020

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists

1 reference

12 December 2020

Biologics in early rheumatoid arthritis

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

12 December 2020

Treatment continuation in patients receiving biological agents or conventional DMARD therapy

1 reference

12 December 2020

Infections in patients with rheumatoid arthritis treated with biologic agents

1 reference

12 December 2020

Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

1 reference

12 December 2020

Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.

1 reference

12 December 2020

Etanercept: a review of its use in rheumatoid arthritis

1 reference

12 December 2020

Clinical and pharmacological experience with etanercept

1 reference

12 December 2020

The pharmacokinetics of etanercept in healthy volunteers

1 reference

12 December 2020

Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis

1 reference

12 December 2020

Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.

1 reference

12 December 2020

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

12 December 2020

Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures

1 reference

12 December 2020

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

1 reference

12 December 2020

1 reference

12 December 2020

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

12 December 2020

Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis

1 reference

12 December 2020

Tumor necrosis factor inhibitors for rheumatoid arthritis

1 reference

12 December 2020

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatolo

1 reference

12 December 2020

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Clinical pharmacokinetics of tumor necrosis factor antagonists.

1 reference

12 December 2020

Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis

1 reference

12 December 2020

Absence of a clinically relevant interaction between etanercept and digoxin.

1 reference

12 December 2020

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

12 December 2020

Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis

1 reference

12 December 2020

Does safety make a difference in selecting the right TNF antagonist?

1 reference

12 December 2020

Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.

1 reference

12 December 2020

Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis

1 reference

12 December 2020

A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.

1 reference

12 December 2020

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

1 reference

12 December 2020

Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis

1 reference

12 December 2020

Comparison of the efficacy of the tumour necrosis factor blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

1 reference

12 December 2020

The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden

1 reference

12 December 2020

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis

1 reference

12 December 2020

A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs

1 reference

12 December 2020

Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results.

1 reference

12 December 2020

Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis

1 reference

12 December 2020

Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis

1 reference

12 December 2020

Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis.

1 reference

12 December 2020

The effectiveness of anti–tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: A population-based study

1 reference

12 December 2020

Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept

1 reference

12 December 2020

Biological agents for rheumatoid arthritis: targeting both physical function and structural damage

1 reference

12 December 2020

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

1 reference

12 December 2020

Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein

1 reference

12 December 2020

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

1 reference

12 December 2020

10.2165/00003495-200767080-00011

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1015740683

0 references

1 reference